# Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

> **NCT07327411** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Refractory Solid Tumors

## Interventions

- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** PD-L1 inhibitor
- **DRUG:** GM-CSF
- **DRUG:** anti-EGFR monoclonal antibody

## Key facts

- **NCT ID:** NCT07327411
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-27
- **Primary completion:** 2027-02-10
- **Final completion:** 2027-11-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327411, "Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT07327411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*